PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Uspaah offers wellness and beauty treatments to clients at their homes, offices and hotels in as little as an hour, all booked via a simple mobile application. This company has reached £264k gross sales y/e Mar 2018, resulting in 58k revenue (-£17k P+L). It utilised the previous Crowdcube investment and its own capital to generate the total accumulated revenue growth of 841% and completed jobs growth of 933%. Presently, it has over 15000 registered users in London and its team has grown from a mere 70 to almost 200 people. With the proceeds, it's planning to scale-up the previous model. Additionally, it aims to double or even triple its client base in the next 18 to 24 months.
days to go:
Expired
investment:
£175,460
An artificially intelligent web-based app for stock market investors to potentially increase their returns. Butterwire's platform aims to solve three common challenges more than 1 million UK investors face: finding high-return opportunities, minimising risk and being aware of sudden market fluctuations.
days to go:
Expired
investment:
Withheld
Investly are an invoice financing marketplace that help European businesses finance their invoices by bringing them the best price from multiple providers. In 2 years they have financed just over £18m worth of invoices.
days to go:
Expired
investment:
£679,085
Andersen EV have developed smart, functional and elegant charging points for electric vehicles. The company's chargers meet the utmost safety standards and the UK Government has already approved the product. Revenue is generated via a subscription model, with many chargers to be located near hotels and businesses. The units are controlled via an app and the firm is in discussions with two major car manufacturers to expand across Europe.
days to go:
Expired
investment:
£726,680
A new form of electric transport in the bike industry with the use of an affordable and simple conversion kit. Swytch have developed a kinetically rechargeable add-on for existing bikes to convert them into eBikes for a range of up to 50 miles. Funding will result in additional units being manufactured and sold at a 70% margin. The products are available online and currently via 20 independent bike dealers, with over 100 more waiting on stock.
days to go:
Expired
investment:
£349,356
Rebel Energy (RE) is an energy supplier on a mission to address inequality and provide everyone with easy access to clean and affordable energy, to eventually eliminate fuel poverty. RE claims that fuel poverty led to 16,500+ cold-related deaths in the UK in 2018. RE argues that as the UK home electricity market enters a phase of growth in a post-COVID world, it will be focused on offering reliable customer service and develop strategies that help people who are struggling with their electricity bills. The company has applied for a B Corporation accreditation. RE asserts that its customer support systems are automated and can handle multiple queries simultaneously. It plans to offer a weekly direct debit payment option. RE will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£503,810
